Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

12.79
Delayed Data
As of May 25
 -0.14 / -1.08%
Today’s Change
8.31
Today|||52-Week Range
32.74
-11.91%
Year-to-Date
Saba Capital Management, L.P. Buys Clough Global Opportunities Fund, General American...
May 25 / GuruFocus News - Paid Partner Content
Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA
May 19 / Zacks.com - Paid Partner Content
Jeff Ubben Buys 1, Sells 1 in 1st Quarter
May 24 / GuruFocus News - Paid Partner Content
5 Things You Must Know Before the Market Opens Friday
May 19 / TheStreet.com - Paid Partner Content
Saba Capital Management, L.P. Buys Clough Global Opportunities Fund, General American...
May 23 / GuruFocus News - Paid Partner Content
Allergan's Irritable Bowel Drug Viberzi Approved in Canada
May 17 / Zacks.com - Paid Partner Content
Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab
May 22 / Zacks.com - Paid Partner Content
Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka
May 16 / Zacks.com - Paid Partner Content
Saba Capital Management, L.P. Buys Clough Global Opportunities Fund, General American...
May 19 / GuruFocus News - Paid Partner Content
Company News for May 12, 2017
May 12 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close12.93
Today’s open12.93
Day’s range12.75 - 13.20
Volume11,085,271
Average volume (3 months)21,286,683
Market cap$4.5B
Dividend yield--
Data as of 4:00pm ET, 05/25/2017

Growth & Valuation

Earnings growth (last year)-716.47%
Earnings growth (this year)-32.57%
Earnings growth (next 5 years)-1.55%
Revenue growth (last year)-7.39%
P/E ratioNM
Price/Sales0.52
Price/Book1.47

Competitors

 Today’s
change
Today’s
% change
TAROTaro Pharmaceutical ...+0.45+0.43%
CTLTCatalent Inc-0.24-0.67%
PTHNPatheon NV-0.07-0.20%
AKRXAkorn Inc+0.06+0.18%
Data as of 3:59pm ET, 05/25/2017

Financials

Next reporting dateAugust 3, 2017
EPS forecast (this quarter)$0.96
Annual revenue (last year)$9.7B
Annual profit (last year)-$2.4B
Net profit margin-24.90%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive VP-Finance
Paul S. Herendeen
Corporate headquarters
Laval, Quă©bec

Forecasts